Zoë Ygj van Lierop, Alyssa A Toorop, Wouter Jc van Ballegoij, Tom Bg Olde Dubbelink, Eva Mm Strijbis, Brigit A de Jong, Bob W van Oosten, Bastiaan Moraal, Charlotte E Teunissen, Bernard Mj Uitdehaag, Joep Killestein, Zoé LE van Kempen
{"title":"在COVID-19大流行期间，多发性硬化症患者的个性化b细胞定制剂量ocrelizumab","authors":"Zoë Ygj van Lierop, Alyssa A Toorop, Wouter Jc van Ballegoij, Tom Bg Olde Dubbelink, Eva Mm Strijbis, Brigit A de Jong, Bob W van Oosten, Bastiaan Moraal, Charlotte E Teunissen, Bernard Mj Uitdehaag, Joep Killestein, Zoé LE van Kempen","doi":"10.1177/13524585211028833","DOIUrl":null,"url":null,"abstract":"<p><p>In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1121-1125"},"PeriodicalIF":5.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211028833","citationCount":"30","resultStr":"{\"title\":\"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.\",\"authors\":\"Zoë Ygj van Lierop, Alyssa A Toorop, Wouter Jc van Ballegoij, Tom Bg Olde Dubbelink, Eva Mm Strijbis, Brigit A de Jong, Bob W van Oosten, Bastiaan Moraal, Charlotte E Teunissen, Bernard Mj Uitdehaag, Joep Killestein, Zoé LE van Kempen\",\"doi\":\"10.1177/13524585211028833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.</p>\",\"PeriodicalId\":520714,\"journal\":{\"name\":\"Multiple sclerosis (Houndmills, Basingstoke, England)\",\"volume\":\" \",\"pages\":\"1121-1125\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/13524585211028833\",\"citationCount\":\"30\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple sclerosis (Houndmills, Basingstoke, England)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13524585211028833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/7/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis (Houndmills, Basingstoke, England)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585211028833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
